Home › Mercks Durham Site Receives U.S. FDA Licensure for Varicella Bulk
 

Keywords :   


Mercks Durham Site Receives U.S. FDA Licensure for Varicella Bulk

2013-09-04 21:50:12| Merck.com - Corporate News

Dateline City: DURHAM, N.C. Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to manufacture bulk varicella at the companys site in Durham, N.C., for use in Mercks vaccines to protect against chickenpox and shingles. The approval will enable the site to produce bulk varicella supply for the U.S. and help boost Mercks overall global supply capabilities. In 2010, the site was approved to produce finished chickenpox vaccines. Language: English Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: site bulk receives durham

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.07Tropical Storm Beryl Graphics
05.07Atlantic Tropical Weather Outlook
05.07Tropical Storm Beryl Public Advisory Number 28A
05.07Summary for Tropical Storm Beryl (AT2/AL022024)
05.07Still no sign of herd rebuilding
05.07Eastern North Pacific Tropical Weather Outlook
05.07Tubi and Pluto lead U.S. surge in free streaming
05.07Tubi free streaming service launches in the UK
More »